The Medicines and Healthcare products Regulatory Agency (MHRA) has issued a statement, following the very encouraging’ results reported by Pfizer on its potential coronavirus (COVID-19) vaccine. The MHRA has stated that it may approve the potential vaccine’s use via a temporary authorisation route known as regulation 174, as well as through the full marketing authorisation procedure. MHRA scientists and clinicians will review the safety, quality and effectiveness data before seeking advice from the government’s independent advisory body, the Commission on Human Medicines.
